Healthy Clinical Trial
Official title:
An Examination Into the Effects of a Nutraceutical Supplement on Cognition, Stress, and Eye and Skin Health in Adults With Self-reported Cognitive Complaints: a Randomised, Double-blind, Placebo-controlled Trial
NCT number | NCT05941949 |
Other study ID # | PHX 1.2 |
Secondary ID | |
Status | Recruiting |
Phase | N/A |
First received | |
Last updated | |
Start date | July 5, 2023 |
Est. completion date | June 2024 |
This is a prospective, placebo controlled study, examining the effects of dietary supplement's effects on cognition and confirming safety.
Status | Recruiting |
Enrollment | 110 |
Est. completion date | June 2024 |
Est. primary completion date | January 2024 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 40 Years to 70 Years |
Eligibility | Inclusion Criteria: - Health Individuals - Residing in independent living accommodations - Subjective report of memory or attention problems by answering 'yes' to the following questions: Do you have problems with your memory, attention, or concentration? - Non-smoker - Body Mass Index (BMI) between 18-35 kg/m2 - No plan to commence new treatments over the study period - Understand, willing and able to comply with all study procedures - Willing to provide a personally signed and dated informed consent form detailing all pertinent aspects of the study Exclusion Criteria: - Diagnosis of dementia based on the revised National Institute on Aging-Alzheimer's Association (NIA/AA) criteria - A score below the 5th percentile for age, education, and gender on the Telephone Interview for Cognitive Status (TICS-M) - Suffering from recently diagnosed or unmanaged medical conditions including but not limited to diabetes, hyper/hypotension, cardiovascular disease, gallbladder disease, autoimmune disease, endocrine disease, or cancer/malignancy - Diagnosis of a psychiatric disease (other than mild-to moderate depression of anxiety) and/or neurological condition/disease (e.g. Parkinson's, Alzheimer's disease) - History of paralysis, stroke or seizures or head injury (with loss of consciousness) - Regular medication intake including but not limited to anticholinergics, acetylcholinesterase inhibiters, or steroid medications. - Taking vitamins or herbal supplements that are reasonably expected to influence study measures - In the last 6 month, commenced or changed the dose of nutritional and/or herbal supplements that may impact on treatment outcome - Alcohol intake greater than 14 standard drinks per week - Current or 12-month history of illicit drug abuse - Pregnant women, women who are Brest feeding, or women who intend to fall pregnant - Any significant surgeries over the last year - Planned major lifestyle change in the next 3 months |
Country | Name | City | State |
---|---|---|---|
Australia | Clinical Research Australia | Duncraig | Western Austrailia |
Lead Sponsor | Collaborator |
---|---|
Pharmanex | Clinical Research Australia |
Australia,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Change in Ocular Surface Disease Index score | Determine the change in Ocular Surface Disease Index score | Baseline, Week 4, Week 8, Week 12 | |
Other | Change in diastolic blood pressure measurement (safety measure) | Determine change in diastolic blood pressure changes using sphygmomanometer | Baseline and Week 12 | |
Other | Change in systolic blood pressure measurement (safety measure) | Determine change in systolic blood pressure measurement using sphygmomanometer | Baseline and Week 12 | |
Primary | Change in working memory | Determine change in working memory as measured by the Numeric Working Memory Test | Baseline and Week 12 | |
Primary | Change in Working memory by Corsi Block tasks | Determine if working memory change by doing Corsi blocks task | Baseline and Week 12 | |
Primary | Change in verbal learning and memory | Determine if verbal learning and memory change using total score on Rey Auditory Verbal Learning test trials 1 to 5 | Baseline and Week 12 | |
Primary | Change in episodic memory | Determine change in episodic memory as measured by Rey Auditory Verbal Learning Test delayed recall and computerized location learning task | Baseline and Week 12 | |
Secondary | Change in accuracy of attention | Determine change inaccuracy of attention as measured by the choice reaction time and digit vigilance task (percent correct) | Baseline and Week 12 | |
Secondary | Change in the Everyday Memory | Determine the change in the Everyday Memory Questionnaire total score | Baseline, Week 4, Week 8, Week 12 | |
Secondary | Change in the Perceived Stress score | Determine the change in the Perceived Stress Questionnaire total score | Baseline, Week 4, Week 8, Week 12 | |
Secondary | Change in the World Health Organization score | Determine the change in the World Health Organization-5 (WHO-5) score | Baseline, Week 4, Week 8, Week 12 | |
Secondary | Change in oxidative stress marker | Determine change in plasma malondialdehyde | Baseline and Week 12 | |
Secondary | Change in plasma Tumor Necrosis Factor-alpha concentrations | Determine change in plasma Tumor Necrosis Factor concentrations | Baseline and Week 12 | |
Secondary | Change in marker of inflammation in the plasma | Determine the change in the plasma marker (interleukin-6-alpha concentrations | Baseline and Week 12 | |
Secondary | Change in plasma Brain-derived neurotropic factor concentrations | Determine the change in plasma Brain-derived neurotropic factor concentrations | Baseline and Week 12 | |
Secondary | Change in Skin Carotenoid Score | Determine the change in Skin Carotenoid Scores using Raman spectroscopy (BioPhotonic Scanner) | Baseline and Week 12 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06052553 -
A Study of TopSpin360 Training Device
|
N/A | |
Completed |
NCT05511077 -
Biomarkers of Oat Product Intake: The BiOAT Marker Study
|
N/A | |
Recruiting |
NCT04632485 -
Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
|
||
Completed |
NCT05931237 -
Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults
|
N/A | |
Terminated |
NCT04556032 -
Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women
|
N/A | |
Completed |
NCT04527718 -
Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers
|
Phase 1 | |
Completed |
NCT04065295 -
A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225
|
Phase 1 | |
Completed |
NCT04107441 -
AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects
|
Phase 1 | |
Completed |
NCT04998695 -
Health Effects of Consuming Olive Pomace Oil
|
N/A | |
Completed |
NCT01442831 -
Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects
|
Phase 1 | |
Terminated |
NCT05934942 -
A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood
|
Phase 1 | |
Recruiting |
NCT05525845 -
Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI
|
N/A | |
Completed |
NCT05515328 -
A Study in Healthy Men to Test How BI 685509 is Processed in the Body
|
Phase 1 | |
Completed |
NCT04967157 -
Cognitive Effects of Citicoline on Attention in Healthy Men and Women
|
N/A | |
Completed |
NCT05030857 -
Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects
|
Phase 1 | |
Recruiting |
NCT04714294 -
Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers
|
Phase 1 | |
Recruiting |
NCT04494269 -
A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls
|
Phase 1 | |
Completed |
NCT04539756 -
Writing Activities and Emotions
|
N/A | |
Recruiting |
NCT04098510 -
Concentration of MitoQ in Human Skeletal Muscle
|
N/A | |
Completed |
NCT03308110 -
Bioavailability and Food Effect Study of Two Formulations of PF-06650833
|
Phase 1 |